Author Archives: Bruno Quinney

#AI #Oncology #Precision medicine

Collaboration to advance precision oncology therapy 

Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.  The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.  TH9619, developed by One-carbon Therapeutics, is a first-in-class,… Read More

#Business & Investment #News

Heart in a box
#Biotech #Cardio #IsomAb

IsomAb appoints CEO to lead development of angina treatment 

Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA).  Brainin arrives with experience in cardiovascular medicine, clinical research, and venture investing across EU and US biotechnology companies. He has previously invested in… Read More

#News

A laboratory mouse
#ischaemic stroke #Stroke #The University of Manchester

Clot-busting drug could harm stroke treatment response 

A clot-busting drug may stop promising stroke medicine from working properly, research reveals.  Researchers at the University of Manchester found the clot-busting therapy, known as tissue plasminogen activator (tPA), interacts negatively with the anti-inflammatory treatment anakinra, highlighting the need for new stroke therapies alongside existing standard care. Read More

#News

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

#Clinical trial #Evotec #Kidney cancer

Evotec to receive $10m as kidney cancer trial launches 

Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway.  Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.   The first-in-human study brings into the clinic a novel CELMoD or… Read More

#Business & Investment #News

Lilly Biotechnology Center
#Alzheimer's #Eli Lilly #National Institute for Health and Care Excellence (NICE) #NHS

Lilly wins appeal for donanemab, drug to be reconsidered for NHS 

Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use.  The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More

#News

CAR-T in multiple myeloma
#Australia #CAR-T #Myeloma

TGA approves trial for first-in-human multiple myeloma therapy

Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma.  The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre (Peter Mac), is a KMA.CAR T-cell immunotherapy. The novel autologous CAR-T cell therapy targets Kappa Myeloma Antigen (KMA), a receptor found only on… Read More

#News #Regulatory

Cancer patient receives chemotherapy via IV
#Clinical trial #Financing #Solid tumours

Mestag raises $40m to advance therapeutic cancer treatment 

Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment.  The closing of the financing round, led by life science investors SV Health Investors and Johnson & Johnson Innovation, brings total funds raised to over $95 million.  The funding is set to support the Phase I STARLYS clinical… Read More

#Business & Investment #News

#Fast Track designation #FDA #Rare diseases

FDA grants Fast Track Designation to rare disease treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for the rare paediatric disease late-infantile neuronal ceroid lipofuscinosis (LINCL/CLN2 disease).  PLX-200, developed by biotechnology company Polaryx Therapeutics, will now undergo an expedited review with the potential to address the paediatric disease with unmet need.  The treatment is… Read More

#News #Regulatory

#AI #Genomics #PacBio

Genomics initiative could boost AI-designed therapeutics 

A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics.  The Trillion Gene Atlas, developed by Basecamp Research in collaboration with Anthropic, Ultima Genomics, PacBio, and NVIDIA AI infrastructure aims to expand known evolutionary genetic diversity… Read More

#News

Theranostic radiopharmaceuticals
#Aptamer Group #Biotech #Radiopharmaceuticals

Radiopharmaceutical programme to develop therapeutic targets 

Biotechnology company Aptamer Group has launched a radiopharmaceutical programme to develop new therapeutic targets.  The programme, launched in collaboration with Radiopharmium, will look to develop three strategic therapeutic targets across high-value clinical indications.  The targets were identified through Aptamer’s Optimer platform and will now be progressed through in vitro… Read More

#News

#Biotech #Cancer research #Head and neck cancer

Outrun to develop treatment for head and neck cancer 

Biotechnology company Outrun Therapeutics has announced its lead programme for the treatment of HPV positive head and neck cancer.  The company has selected an E6AP inhibitor strategy as the lead programme from its first-in-class therapeutic pipeline, developed through its proprietary XL discovery platform. The platform has been… Read More

#Cancer Research #News

#Regulatory #Research and development

Gaining competitive advantages in pharma

Jessica Del Vecchio, Economic Development Manager for The Office of Economic Development in the City of Boca Raton, asks how permitting assistance can offer a competitive advantage during pharma site selection.  The pharmaceutical and healthcare sectors are defined by their relentless pace of innovation and their critical need for strategic expansion. As companies look to establish new regional headquarters, R&D centres, or… Read More

#Exclusive Content

Blood cancer
#Blood cancer #Cancer Research UK #NHS

First patient dosed in ROR1-positive blood cancer treatment 

The first patient has been dosed in a treatment for ROR1-positive blood cancers.  NVG-222 is a bispecific T-cell engager targeting ROR1 and CD3, developed by biotechnology company NovalGen.  The drug is the first therapeutic candidate to use NovalGen’s proprietary AutoRegulation technology, an innovation designed to mitigate excessive… Read More

#Cancer Research #News

#Drug discovery #Orphan drugs #Rare diseases

Rare disease drugs to generate $400bn by 2032, report reveals 

Rare disease therapies could generate over $400 billion in global sales by 2032, a new report reveals.   Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of… Read More

#Business & Investment #News

#Biomarkers #Drug discovery #Epigenetics #Idiopathic pulmonary fibrosis #Medicines Discovery Catapult

How spatial epigenetics is unlocking new frontiers in drug discovery

Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery.   Epigenetics, once seen as a cryptic mix of marks on our DNA, is now central to our understanding of gene regulation in health and disease. Until recently, we studied epigenetics only in bulk tissues or single cells. But with emerging… Read More

#Exclusive Content